AtriCure, Inc. (ATRC)
USD 30.61
(-3.1%)
USD 30.61
(-3.1%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 | -9.81 Million USD | -189.42% |
| 2022 | 10.97 Million USD | -65.69% |
| 2021 | 31.99 Million USD | -0.2% |
| 2020 | 32.05 Million USD | -33.13% |
| 2019 | 47.93 Million USD | 136.98% |
| 2018 | 20.22 Million USD | 29.57% |
| 2017 | 15.61 Million USD | 6.32% |
| 2016 | 14.68 Million USD | 252.91% |
| 2015 | -9.6 Million USD | 60.52% |
| 2014 | -24.32 Million USD | -188.19% |
| 2013 | -8.44 Million USD | -1336.02% |
| 2012 | 683 Thousand USD | 120.76% |
| 2011 | -3.29 Million USD | -139.17% |
| 2010 | -1.37 Million USD | 77.94% |
| 2009 | -6.23 Million USD | -15.95% |
| 2008 | -5.37 Million USD | 54.78% |
| 2007 | -11.89 Million USD | 13.86% |
| 2006 | -13.8 Million USD | 46.8% |
| 2005 | -25.95 Million USD | -401.45% |
| 2004 | -5.17 Million USD | 0.0% |
| 2003 | - USD | 0.0% |
| 2002 | - USD | 0.0% |
| 2001 | - USD | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 Q2 | -30.71 Million USD | -395.49% |
| 2024 Q1 | 10.39 Million USD | 205.91% |
| 2024 Q3 | -68.47 Million USD | -73.21% |
| 2023 Q3 | -6.22 Million USD | -181.95% |
| 2023 Q4 | -9.81 Million USD | -57.74% |
| 2023 FY | -9.81 Million USD | -189.42% |
| 2023 Q1 | -2.11 Million USD | -119.28% |
| 2023 Q2 | 7.59 Million USD | 458.88% |
| 2022 Q4 | 10.97 Million USD | -57.76% |
| 2022 Q1 | 47.17 Million USD | 47.46% |
| 2022 Q3 | 25.99 Million USD | 27.33% |
| 2022 FY | 10.97 Million USD | -65.69% |
| 2022 Q2 | 20.41 Million USD | -56.73% |
| 2021 FY | 31.99 Million USD | -0.2% |
| 2021 Q1 | -11.8 Million USD | -136.83% |
| 2021 Q2 | 6.91 Million USD | 158.59% |
| 2021 Q3 | 32.95 Million USD | 376.56% |
| 2021 Q4 | 31.99 Million USD | -2.93% |
| 2020 Q2 | -13.7 Million USD | -125.26% |
| 2020 FY | 32.05 Million USD | -33.13% |
| 2020 Q1 | 54.27 Million USD | 13.21% |
| 2020 Q4 | 32.05 Million USD | -22.14% |
| 2020 Q3 | 41.17 Million USD | 400.31% |
| 2019 Q2 | 28.57 Million USD | -14.43% |
| 2019 FY | 47.93 Million USD | 136.98% |
| 2019 Q1 | 33.39 Million USD | 65.1% |
| 2019 Q4 | 47.93 Million USD | 10.89% |
| 2019 Q3 | 43.23 Million USD | 51.27% |
| 2018 Q3 | 34.45 Million USD | -10.78% |
| 2018 FY | 20.22 Million USD | 29.57% |
| 2018 Q4 | 20.22 Million USD | -41.28% |
| 2018 Q2 | 38.61 Million USD | 23.43% |
| 2018 Q1 | 31.28 Million USD | 100.38% |
| 2017 Q3 | 19.24 Million USD | 8.46% |
| 2017 Q4 | 15.61 Million USD | -18.89% |
| 2017 Q1 | 19.67 Million USD | 33.97% |
| 2017 FY | 15.61 Million USD | 6.32% |
| 2017 Q2 | 17.74 Million USD | -9.79% |
| 2016 Q4 | 14.68 Million USD | -35.68% |
| 2016 Q3 | 22.83 Million USD | 19.98% |
| 2016 Q2 | 19.02 Million USD | 383.42% |
| 2016 Q1 | -6.71 Million USD | 30.09% |
| 2016 FY | 14.68 Million USD | 252.91% |
| 2015 Q4 | -9.6 Million USD | 36.29% |
| 2015 Q1 | -17.48 Million USD | 28.14% |
| 2015 Q2 | -20.68 Million USD | -18.29% |
| 2015 Q3 | -15.07 Million USD | 27.11% |
| 2015 FY | -9.6 Million USD | 60.52% |
| 2014 Q3 | -32.93 Million USD | 21.36% |
| 2014 Q1 | -68.53 Million USD | -711.8% |
| 2014 FY | -24.32 Million USD | -188.19% |
| 2014 Q2 | -41.87 Million USD | 38.9% |
| 2014 Q4 | -24.32 Million USD | 26.12% |
| 2013 Q2 | -23.62 Million USD | -3.36% |
| 2013 Q4 | -8.44 Million USD | 55.24% |
| 2013 FY | -8.44 Million USD | -1336.02% |
| 2013 Q1 | -22.85 Million USD | -3446.27% |
| 2013 Q3 | -18.86 Million USD | 20.15% |
| 2012 Q4 | 683 Thousand USD | -2.01% |
| 2012 Q2 | 745 Thousand USD | 149.61% |
| 2012 Q1 | -1.5 Million USD | 54.36% |
| 2012 FY | 683 Thousand USD | 120.76% |
| 2012 Q3 | 697 Thousand USD | -6.44% |
| 2011 FY | -3.29 Million USD | -139.17% |
| 2011 Q4 | -3.29 Million USD | -197.08% |
| 2011 Q3 | 3.38 Million USD | 9.61% |
| 2011 Q2 | 3.09 Million USD | 3228.18% |
| 2011 Q1 | -98.84 Thousand USD | 92.82% |
| 2010 Q1 | 738.81 Thousand USD | 118.43% |
| 2010 FY | -1.37 Million USD | 77.94% |
| 2010 Q4 | -1.37 Million USD | -803.02% |
| 2010 Q3 | -152.34 Thousand USD | 94.87% |
| 2010 Q2 | -2.96 Million USD | -501.65% |
| 2009 Q3 | -5.27 Million USD | 33.59% |
| 2009 FY | -6.23 Million USD | -15.95% |
| 2009 Q1 | -8.54 Million USD | -58.91% |
| 2009 Q2 | -7.94 Million USD | 7.02% |
| 2009 Q4 | -4 Million USD | 24.04% |
| 2008 Q2 | -9.45 Million USD | 23.33% |
| 2008 FY | -5.37 Million USD | 54.78% |
| 2008 Q4 | -5.37 Million USD | 13.28% |
| 2008 Q3 | -6.2 Million USD | 34.39% |
| 2008 Q1 | -12.32 Million USD | -3.66% |
| 2007 Q4 | -11.89 Million USD | 27.63% |
| 2007 Q2 | -26.84 Million USD | -120.09% |
| 2007 Q1 | -12.19 Million USD | 11.66% |
| 2007 FY | -11.89 Million USD | 13.86% |
| 2007 Q3 | -16.43 Million USD | 38.78% |
| 2006 FY | -13.8 Million USD | 46.8% |
| 2006 Q1 | -21.69 Million USD | 16.4% |
| 2006 Q3 | -14.63 Million USD | 21.06% |
| 2006 Q2 | -18.54 Million USD | 14.53% |
| 2006 Q4 | -13.8 Million USD | 5.68% |
| 2005 Q2 | -1.09 Million USD | 55.51% |
| 2005 Q4 | -25.95 Million USD | 29.42% |
| 2005 Q1 | -2.45 Million USD | 52.63% |
| 2005 Q3 | -36.76 Million USD | -3270.98% |
| 2005 FY | -25.95 Million USD | -401.45% |
| 2004 FY | -5.17 Million USD | 0.0% |
| 2004 Q4 | -5.17 Million USD | 0.0% |
| 2003 FY | - USD | 0.0% |
| 2002 FY | - USD | 0.0% |
| 2001 FY | - USD | 0.0% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| Akoya Biosciences, Inc. | 2.58 Million USD | 480.318% |
| AngioDynamics, Inc. | -70.14 Million USD | 86.006% |
| Avinger, Inc. | 10.12 Million USD | 196.996% |
| Azenta, Inc. | -618.47 Million USD | 98.413% |
| BioLife Solutions, Inc. | 7.25 Million USD | 235.337% |
| The Cooper Companies, Inc. | 2.44 Billion USD | 100.401% |
| Daxor Corporation | 755.65 Thousand USD | 1398.999% |
| Ekso Bionics Holdings, Inc. | -1.47 Million USD | -567.755% |
| Femasys Inc. | -15.01 Million USD | 34.626% |
| GlucoTrack, Inc. | -4.29 Million USD | -128.492% |
| Harvard Bioscience, Inc. | 38.49 Million USD | 125.503% |
| Hologic, Inc. | 374.4 Million USD | 102.622% |
| ICU Medical, Inc. | 1.45 Billion USD | 100.677% |
| Intuitive Surgical, Inc. | -2.66 Billion USD | 99.631% |
| KORU Medical Systems, Inc. | -7.03 Million USD | -39.489% |
| LeMaitre Vascular, Inc. | -5.17 Million USD | -89.718% |
| Innovative Eyewear, Inc. | -4.28 Million USD | -128.947% |
| Innovative Eyewear, Inc. | -4.28 Million USD | -128.947% |
| Masimo Corporation | 804 Million USD | 101.221% |
| Microbot Medical Inc. | -2.28 Million USD | -329.396% |
| Meihua International Medical Technologies Co., Ltd. | -9.59 Million USD | -2.295% |
| Merit Medical Systems, Inc. | 302.22 Million USD | 103.248% |
| Nephros, Inc. | -2.47 Million USD | -297.248% |
| NovoCure Limited | 355.42 Million USD | 102.762% |
| NEXGEL, Inc. | 98 Thousand USD | 10116.327% |
| NEXGEL, Inc. | 98 Thousand USD | 10116.327% |
| Singular Genomics Systems, Inc. | 59.05 Million USD | 116.622% |
| OraSure Technologies, Inc. | -276.9 Million USD | 96.455% |
| Pro-Dex, Inc. | 10.91 Million USD | 189.923% |
| Pulse Biosciences, Inc. | -35.22 Million USD | 72.13% |
| Predictive Oncology Inc. | -5.87 Million USD | -67.171% |
| Precision Optics Corporation, Inc. | 3.02 Million USD | 424.048% |
| QuidelOrtho Corporation | 2.49 Billion USD | 100.393% |
| Repligen Corporation | -39.51 Million USD | 75.161% |
| Sanara MedTech Inc. | 6.64 Million USD | 247.722% |
| STAAR Surgical Company | -147.2 Million USD | 93.332% |
| Sharps Technology, Inc. | -3.01 Million USD | -225.798% |
| Utah Medical Products, Inc. | -92.52 Million USD | 89.391% |
| DENTSPLY SIRONA Inc. | 1.96 Billion USD | 100.5% |
| Jin Medical International Ltd. | -2.81 Million USD | -248.517% |